These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17909358)

  • 1. Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.
    Krug LM; Milton DT; Jungbluth AA; Chen LC; Quaia E; Pandit-Taskar N; Nagel A; Jones J; Kris MG; Finn R; Smith-Jones P; Scott AM; Old L; Divgi C
    J Thorac Oncol; 2007 Oct; 2(10):947-52. PubMed ID: 17909358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by (111)Indium-labeled humanized monoclonal antibody 3S193.
    Quaia E; Krug LM; Pandit-Taskar N; Nagel A; Reuter VE; Humm J; Divgi C
    Eur J Radiol; 2008 Aug; 67(2):292-299. PubMed ID: 17714905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
    Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
    Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
    Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
    J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Cancer Res; 2000 Sep; 60(17):4804-11. PubMed ID: 10987290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.
    Scott AM; Tebbutt N; Lee FT; Cavicchiolo T; Liu Z; Gill S; Poon AM; Hopkins W; Smyth FE; Murone C; MacGregor D; Papenfuss AT; Chappell B; Saunder TH; Brechbiel MW; Davis ID; Murphy R; Chong G; Hoffman EW; Old LJ
    Clin Cancer Res; 2007 Jun; 13(11):3286-92. PubMed ID: 17545534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
    Boghaert ER; Sridharan L; Armellino DC; Khandke KM; DiJoseph JF; Kunz A; Dougher MM; Jiang F; Kalyandrug LB; Hamann PR; Frost P; Damle NK
    Clin Cancer Res; 2004 Jul; 10(13):4538-49. PubMed ID: 15240546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
    Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
    Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
    Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels.
    Lövqvist A; Humm JL; Sheikh A; Finn RD; Koziorowski J; Ruan S; Pentlow KS; Jungbluth A; Welt S; Lee FT; Brechbiel MW; Larson SM
    J Nucl Med; 2001 Aug; 42(8):1281-7. PubMed ID: 11483692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
    Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolocalization of human small cell lung cancer and antigen-positive normal tissues using monoclonal antibody LS2D617.
    Wilson BS; Petrella E; Lowe SR; Lien K; Mackensen DG; Gridley DS; Stickney DR
    Cancer Res; 1990 May; 50(10):3124-30. PubMed ID: 2159374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
    Lynch TJ; Lambert JM; Coral F; Shefner J; Wen P; Blattler WA; Collinson AR; Ariniello PD; Braman G; Cook S; Esseltine D; Elias A; Skarin A; Ritz J
    J Clin Oncol; 1997 Feb; 15(2):723-34. PubMed ID: 9053498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer.
    Chaudhry A; Carrasquillo JA; Avis IL; Shuke N; Reynolds JC; Bartholomew R; Larson SM; Cuttitta F; Johnson BE; Mulshine JL
    Clin Cancer Res; 1999 Nov; 5(11):3385-93. PubMed ID: 10589749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
    Smaletz O; Diz MD; do Carmo CC; Sabbaga J; Cunha-Junior GF; Azevedo SJ; Maluf FC; Barrios CH; Costa RL; Fontana AG; Madrigal V; Wainstein AJ; Yeda FP; Alves VA; Moro AM; Blasbalg R; Scott AM; Hoffman EW
    Gynecol Oncol; 2015 Aug; 138(2):272-7. PubMed ID: 26026738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens.
    Ramsland PA; Farrugia W; Bradford TM; Mark Hogarth P; Scott AM
    J Mol Biol; 2004 Jul; 340(4):809-18. PubMed ID: 15223322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses.
    Liu Z; Panousis C; Smyth FE; Murphy R; Wirth V; Cartwright G; Johns TG; Scott AM
    Hybrid Hybridomics; 2003 Aug; 22(4):219-28. PubMed ID: 14511567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.